Daiichi Sankyo launches four new generic drugs through its Daiichi Sankyo Espha Subsidiary

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that its Japan generics subsidiary, Daiichi Sankyo Espha, today launched two new generic drugs with two new active ingredients and two generic drugs with an additional standard.

Overview

1. Product names/therapeutic categories

2. Product attributes
Daiichi Sankyo Espha has created innovative labeling on tablets and PTP sheets to prevent medical error and improve ease of use and hails these value added generics as “premium generics.”

Tablets

• Printing on tablets (for Valaciclovir Tablets/ Donepezil Hydrochloride Tablets, Donepezil Hydrochloride OD Tablets)
• The product name, dosage per tablet and company name will be printed on both sides to be easily distinguishable.
• With a new inkjet printing method, it is now possible to print double-sided OD tablets as well.

Tablet taste (Donepezil Hydrochloride OD Tablets)

• Daiichi Sankyo is working to improve medication adherence of OD tablets (oral dispersing tablets) through a dosage form design that reduces the bitter taste of the drug.

PTP packaging

Pitch control (excluding Azithromycin Tablets)

• Through pitch control, it is possible to display the product name and dosage on each pill, making it easier for patients to recognize the pill even if it is taken out of the PTP sheet.

Design that allows for easy identification (for all new items)

• Special markings on both sides of the PTP sheets allow for improved identification.

GS1 data barcode (for all new items)

• The GS1 data barcode is marked on each tablet and each slit to prevent medication errors.

PTP packaging within packaging for patients (for Azithromycin Tablets only)

• Daiichi Sankyo Espha has developed “packaging for patients,” which is equivalent to the standard item, in order to improve medication adherence. The package width has been trimmed, PTP sheets made easier to remove, and the material used takes into account disposal.